Alector's (ALEC) "Overweight" Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Alector (NASDAQ:ALEC - Free Report) in a research report sent to investors on Thursday, Benzinga reports.

Separately, HC Wainwright reaffirmed a buy rating and set a $41.00 price objective on shares of Alector in a research report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Alector currently has an average rating of Moderate Buy and an average price target of $14.00.

Alector Stock Performance

Shares of Alector stock traded up $0.01 on Thursday, hitting $5.20. The company's stock had a trading volume of 592,052 shares, compared to its average volume of 651,859. The firm has a fifty day moving average price of $5.86 and a 200-day moving average price of $6.13. Alector has a 1 year low of $3.66 and a 1 year high of $9.06. The company has a market capitalization of $501.23 million, a price-to-earnings ratio of -3.35 and a beta of 0.82.

Alector (NASDAQ:ALEC - Get Free Report) last posted its earnings results on Tuesday, February 27th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.31. The firm had revenue of $15.19 million for the quarter, compared to analyst estimates of $8.35 million. Alector had a negative return on equity of 77.15% and a negative net margin of 134.34%. As a group, analysts forecast that Alector will post -1.89 EPS for the current year.

Insider Activity at Alector

In related news, CFO Marc Grasso sold 5,716 shares of the business's stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $6.92, for a total transaction of $39,554.72. Following the completion of the sale, the chief financial officer now owns 144,957 shares of the company's stock, valued at approximately $1,003,102.44. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, insider Gary Romano sold 6,001 shares of the business's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $6.92, for a total transaction of $41,526.92. Following the transaction, the insider now directly owns 196,313 shares in the company, valued at approximately $1,358,485.96. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Marc Grasso sold 5,716 shares of the business's stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $6.92, for a total transaction of $39,554.72. Following the completion of the sale, the chief financial officer now directly owns 144,957 shares of the company's stock, valued at $1,003,102.44. The disclosure for this sale can be found here. Insiders have sold 30,554 shares of company stock valued at $211,434 over the last ninety days. Corporate insiders own 14.00% of the company's stock.

Institutional Investors Weigh In On Alector

Several hedge funds have recently modified their holdings of ALEC. FMR LLC lifted its stake in Alector by 58.3% during the third quarter. FMR LLC now owns 12,172,045 shares of the company's stock worth $78,875,000 after purchasing an additional 4,481,420 shares during the period. Euclidean Capital LLC lifted its stake in shares of Alector by 33.3% in the 3rd quarter. Euclidean Capital LLC now owns 1,307,858 shares of the company's stock valued at $8,475,000 after purchasing an additional 326,964 shares during the period. Jacobs Levy Equity Management Inc. raised its position in shares of Alector by 33.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 778,077 shares of the company's stock valued at $5,042,000 after acquiring an additional 195,411 shares during the period. Panagora Asset Management Inc. increased its position in shares of Alector by 21.2% in the 3rd quarter. Panagora Asset Management Inc. now owns 293,534 shares of the company's stock valued at $1,902,000 after buying an additional 51,440 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Alector during the fourth quarter worth about $1,920,000. 85.83% of the stock is owned by institutional investors.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.